Taurolidine
Defencath (taurolidine) is a small molecule pharmaceutical. Taurolidine was first approved as Defencath on 2023-11-15.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Combinations
Defencath
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| defencath | New Drug Application | 2023-12-21 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
HEPARIN SODIUM / TAUROLIDINE, DEFENCATH, CORMEDIX | |||
| 2033-11-15 | GAIN | ||
| 2028-11-15 | NCE | ||
HCPCS
No data
Clinical
Clinical Trials
23 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Catheter-related infections | D055499 | — | — | — | — | 1 | 2 | 1 | 4 |
| Chronic kidney failure | D007676 | EFO_0003884 | N18.6 | — | — | 2 | 1 | — | 3 |
| Renal dialysis | D006435 | EFO_0010690 | Z99.2 | — | — | 1 | 1 | — | 2 |
| Thrombosis | D013927 | — | — | — | — | — | 1 | — | 1 |
| Central venous catheters | D062905 | — | — | — | — | — | 1 | — | 1 |
| Home parenteral nutrition | D016331 | — | — | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Infections | D007239 | EFO_0000544 | — | — | — | 2 | — | — | 2 |
| Sepsis | D018805 | HP_0100806 | A41.9 | — | — | 1 | — | 1 | 2 |
| Neoplasms | D009369 | — | C80 | — | — | 1 | — | — | 1 |
| Bacteremia | D016470 | EFO_0003033 | R78.81 | — | — | 1 | — | — | 1 |
| Parenteral nutrition | D010288 | — | — | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Periodontitis | D010518 | EFO_0000649 | K05.3 | 1 | 2 | — | — | — | 2 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Central nervous system neoplasms | D016543 | — | — | 1 | — | — | — | — | 1 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 1 | — | — | — | — | 1 |
| Fallopian tube neoplasms | D005185 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Taurolidine |
| INN | taurolidine |
| Description | Taurolidine is a thiadiazinane. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | O=S1(=O)CCN(CN2CCS(=O)(=O)NC2)CN1 |
Identifiers
| PDB | — |
| CAS-ID | 19388-87-5 |
| RxCUI | — |
| ChEMBL ID | CHEMBL2105420 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB12473 |
| UNII ID | 8OBZ1M4V3V (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 609 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use